The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Toxicological Risks of Selected Flame-Retardant Chemicals
Cancer
There are inadequate data to assess the carcinogenicity of antimony trioxide from dermal or oral exposures.
Inhalation (Particles)
The average room-air concentration and average exposure concentration for antimony trioxide were obtained as described for the noncancer risk assessment of particles. The estimated time-averaged exposure concentration is 0.24 µg/m3. Using the inhalation unit cancer risk (cancer potency factor) of 7.1×10−4/µg antimony trioxide/m3, the lifetime excess cancer risk estimate from exposure to antimony trioxide as particles is 1.7×10−4. However, the inhalation unit risk (cancer potency factor) of antimony trioxide is itself suspect (see Hazard Identification Section). Furthermore, even if the reservations concerning the study by Watt (1983) are discounted and the inhalation unit risk is considered to be accurate, better exposure assessment is required before any definitive conclusions can be drawn about the carcinogenic risk from antimony trioxide via inhalation in the particulate phase.
Inhalation (Vapors)
Antimony trioxide has negligible vapor pressure at ambient temperatures, so antimony trioxide used as a flame retardant in upholstery fabric is not likely to pose a cancer risk for exposure to vapors.
RECOMMENDATIONS FROM OTHER ORGANIZATIONS
The American Conference of Governmental Industrial Hygienists (ACGIH) has established a Threshold Limit Value (TLV) for antimony trioxide of 0.5 mg antimony/m3 (AGCIH 1999).
The Occupational Safety and Health Administration (OSHA) and the National Institute for Occupational Safety and Health (NIOSH) do not have standards for exposure to antimony trioxide.
EPA’s inhalation RfC of 0.2 µg antimony trioxide/mg3 is the same as that of the subcommittee.